Biocon Biologics takes charge of Viatris' biosimilars across 120 countries

With the completion of this milestone, Biocon Biologics is now a unique, fully integrated ‘lab to market’ biosimilars company committed to serving millions of patients across the globe," Biocon said in a regulatory filing.

The move sees Biocon Biologics taking charge of all Viatris' biosimilar brands, such as Ogivri, Hertraz (bTrastuzumab), Abevmy (bBevacizumab), Fulphila (bPegfilgrastim), Hulio (bAdalimumab), Nepexto (bEtanercept), Semglee (bGlargine), and Kirsty (bAspart).

These biosimilars cover a diverse portfolio in key therapeutic areas, including diabetology, oncology, and immunology. Notably, most of these products have been developed by Biocon Biologics and are manufactured at the company's state-of-the-art facilities in India and Malaysia.

The direct presence in these global markets positions Biocon Biologics to establish closer connections with patients while strengthening relationships with prescribers and payers. This strategic shift is not only expected to enhance patient reach but also generate significant cost savings for healthcare systems.

With the transition of marketing responsibilities, Biocon Biologics aims to ensure seamless business continuity for patients, prescribers, partners, and healthcare systems. The company's commitment to delivering high-quality biosimilars is reinforced by the consolidation of these brands under its direct management.

Shreehas Tambe, CEO and Managing Director of Biocon Biologics Ltd, said, "I am very proud and excited that we have successfully completed the integration of the acquired business across 120 countries. The conclusion of this final wave of transition is a significant milestone and marks the beginning of Biocon Biologics’ transformation to a fully integrated global company."

Shares of Biocon Ltd ended at ₹254, up by ₹2.40, or 0.95%, on the BSE.